Scientific Data Posters

  1. Key Data Slides from ANA598 Late-Breaker Poster EASL 2010
    45th Annual Meeting of the European Association for the Study of the Liver (EASL) in Vienna, Austria
  2. Safety and Antiviral Activity of ANA598 in Combination with Pegylated Interferon Alpha 2A Plus Ribavirin in Treatment-Naive Genotype 1 Chronic HCV Patients
    45th Annual Meeting of the European Association for the Study of the Liver (EASL) in Vienna, Austria
  3. Enhanced In Vitro Activity of ANA598 in Combination With Other Anti-HCV Agents Support Combination Treatment
    45th Annual Meeting of the European Association for the Study of the Liver (EASL) in Vienna, Austria
  4. In Vitro Combination Studies of ANA598 with Anti-HCV Agents Demonstrates Enhanced Antiviral Activity
    23rd International Conference on Antirival Research (ICAR)
  5. Variant Genotype 1 HCV Viruses Observed in Treatment-Naïve Patients Following Three Days of ANA598 Administration Retain Sensitivity to Subsequent Standard Therapy With PEG-IFNa and Ribavirin (RBV)
    HEPDART 2009
  6. ANA598 displays potent in vitro antiviral activity against diverse clinical isolates of genotype 1 HCV in a transient replicon shuttle vector system.
    American Association for the Study of Liver Diseases, November 2009
  7. ANA773, an Oral Inducer of Endogenous Interferons that Acts Via TLR7, Reduced Serum Viral Load in Patients Chronically Infected with HCV.
    American Association for the Study of Liver Diseases, November 2009
  8. Clinical and Preclinical Studies with ANA773, an Oral Prodrug of a TLR7 Agonist, Suggest Therapeutic Potential in Patients Chronically Infected with HCV.
    The Henry M. and Lillian Stratton Basic Research Single Topic Conference in Atlanta, Georgia
  9. Antiviral Activity of ANA598, a Potent Non-Nucleoside Polymerase Inhibitor, in Chronic Hepatitis C Patients
    44th Annual Meeting of the European Association for the Study of the Liver (EASL) in Copenhagen, Denmark
  10. PK/PD Assessment of a Phase 1 Healthy Volunteer Study with ANA773, an Oral Inducer of Endogenous Interferons That Acts Via TLR7, for the Treatment of HCV
    44th Annual Meeting of the European Association for the Study of the Liver (EASL) in Copenhagen, Denmark
  11. Preclinical Studies of ANA598 Combined with Other Anti-HCV Agents Demonstrate Potential of Combination Treatment
    44th Annual Meeting of the European Association for the Study of the Liver (EASL) in Copenhagen, Denmark
  12. Preclinical and Healthy Volunteer Clinical Studies with ANA773, an Oral Prodrug of a Toll-Like Receptor 7 (TLR7)-Selective Agonist, Suggest Therapeutic Potential in Patients Chronically Infected with Hepatitis C Virus (HCV)
    13th International Symposium of Viral Hepatitis and Liver Disease, March 2009.
  13. Results of A Phase I Safety, Tolerability and Pharmacokinetic Study of ANA598, A Non-nucleoside NS5B Polymerase Inhibitor, in Healthy Volunteers
    American Association for the Study of Liver Diseases, November 2008
  14. In Vitro Studies Demonstrate that Combinations of Antiviral Agents that Include HCV Polymerase Inhibitor ANA598 have the Potential to Overcome Viral Resistance
    American Association for the Study of Liver Diseases, November 2008
  15. Pro-apoptotic effect of the active metabolite of ANA773, a toll-like receptor 7 agonist, on chronic lymphocytic leukemia cells in vitro; synergism in combination with a NF-kB inhibitor
    American Assocation for Cancer Research, April 2008
  16. Dose schedule modulates the pharmacodynamic response to ANA773, a prodrug of a toll-like receptor (TLR)-7 selective-agonist
    American Assocation for Cancer Research, April 2008
  17. Pathway to Selection of a Potent, Well Tolerated Development Candidate in HCV
    21st International Conference on Antiviral Research, April 2008
  18. Pyrrolo[1,2-b]pyridazin-2-ones as potent inhibitors of HCV NS5B polymerase
    Hep DART, December 2007
  19. 4-(1,1-Dioxo-1,4-dihydro-1λ6-benzo[1,4]thiazin-3 -yl)-5-hydroxy-2H-pyridazin-3-ones as novel inhibitors of the HCV NS5B polymerase
    Hep DART, December 2007
  20. ANA598, a Novel Non-Nucleoside Inhibitor of HCV NS5B Polymerase, Exhibits Favorable Pharmacokinetic Properties in Multiple Preclinical Species
    American Association for the Study of Liver Diseases, October 2007
  21. Preclinical Characterization of a Novel, Potent, and Pharmacokinetically Appealing Non-Nucleoside Inhibitor of HCV NS5B Polymerase
    14th International Symposium on Hepatitis C Virus and Related Viruses, September 2007
  22. The active metabolite of the TLR7 agonist prodrug ANA773 activates anti-tumor activity by natural killer cells
    American Assocation for Cancer Research, April 2007
  23. The effect of dose schedule on the pharmacodynamic response to ANA773, a prodrug of a toll-like receptor 7 specific-agonist
    American Assocation for Cancer Research NCI-EORTC, April 2007